Effects of Single-Dose Praziquantel on Morbidity and Mortality Resulting from Intestinal Schistosomiasis
| dc.Faculty | Endemic Diseases | en_US |
| dc.contributor.author | Kheir,M M.;Baraka,O.Z.;Mukhtar,Moawia M.;Homieda,M.M.A | |
| dc.date | 2000 | |
| dc.date.accessioned | 2015-11-19T07:00:59Z | |
| dc.date.available | 2015-11-19T07:00:59Z | |
| dc.date.issued | 2015-11-19 | |
| dc.date.submitted | 2015 | |
| dc.description.abstract | The long-term effect of single-dose praziquantel on morbidity and mortality from Schistosoma mansoni was investigated in surveys in 1987 and 1994 in central Sudan. Prevalence of infection dropped from 53% to 34%, and intensity of infection [400 eggs/g of faeces] from 31% to 18%. There was a reduction in hepatomegaly and hepatosplenomegaly, although splenomegaly alone was unchanged. Prevalence of periportal fibrosis decreased from 14% to 10%. Endoscopic investigation of patients with fibrosis showed a reduction in oesophageal varices from 47% to 30%. Mortality due to bleeding varices was high [community-wide, up to 11/100 infected patients with bleeding]. Thus praziquantel mass treatment can be spaced to a much longer period, reducing the expense of treatment, delivery and distribution - See more at: http://apps.who.int/iris/handle/10665/118947#sthash.Uy0OEmZY.dpuf | en_US |
| dc.identifier.uri | http://khartoumspace.uofk.edu/123456789/17240 | |
| dc.language.iso | en | en_US |
| dc.publisher | EMRO Journal Articles | en_US |
| dc.subject | Praziquantel | en_US |
| dc.subject | Esophageal and Gastric Varices | en_US |
| dc.subject | Schistosomiasis mansoni | en_US |
| dc.subject | Liver Cirrhosis | en_US |
| dc.subject | Schistosomiasis mansoni | en_US |
| dc.subject | Prevalence | en_US |
| dc.title | Effects of Single-Dose Praziquantel on Morbidity and Mortality Resulting from Intestinal Schistosomiasis | en_US |
| dc.type | Publication | en_US |